Cytosorbents’ (CTSO) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $10.00 target price on the medical research company’s stock.

CTSO has been the subject of a number of other reports. StockNews.com started coverage on shares of Cytosorbents in a research note on Saturday, December 28th. They set a “hold” rating for the company. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Cytosorbents presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO stock opened at $0.94 on Friday. The stock has a 50 day moving average price of $0.92 and a 200 day moving average price of $1.02. The firm has a market capitalization of $51.21 million, a P/E ratio of -2.60 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.59.

Hedge Funds Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently made changes to their positions in the company. Atomi Financial Group Inc. purchased a new stake in Cytosorbents in the third quarter worth about $51,000. Geode Capital Management LLC increased its position in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Finally, Sargent Investment Group LLC raised its holdings in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.